Intermediate-Term Graft Loss After Renal Transplantation is Associated With Both Donor-Specific Antibody and Acute Rejection

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Transplantation

• Publication date

  2014-03-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/01.TP.0000438196.30790.66PMID 24595116
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Incidence and Impact of De Novo Donor-Specific Alloantibody in Primary Renal Allografts

  2013influential reference
• Outcomes of living donor renal transplants with a negative cross-match and pretransplant donor-specific antibody.

  2013cited by this paper
• Consensus Guidelines on the Testing and Clinical Management Issues Associated With HLA and Non-HLA Antibodies in Transplantation

  2013cited by this paper
• Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after renal transplantation.

  2012cited by this paper
• De Novo DQ Donor-Specific Antibodies Are Associated With a Significant Risk of Antibody-Mediated Rejection and Transplant Glomerulopathy

  2012cited by this paper
• Evolution and Clinical Pathologic Correlations of De Novo Donor‐Specific HLA Antibody Post Kidney Transplant

  2012influential reference
• Long‐term follow up for anti‐HLA donor specific antibodies postrenal transplantation: high immunogenicity of HLA class II graft molecules

  2011cited by this paper
• Inferior Kidney Allograft Outcomes in Patients With De Novo Donor-Specific Antibodies Are Due to Acute Rejection Episodes

  2011influential reference
• Posttransplant Donor‐Specific Anti‐HLA Antibodies Negatively Impact Pancreas Transplantation Outcome

  2011cited by this paper
• Donor human leukocyte antigen specific antibodies predict development and define prognosis in transplant glomerulopathy.

  2011cited by this paper
• Detection of plasma cells, C4d deposits and donor-specific antibodies on sequential graft biopsies of renal transplant recipients with chronic dysfunction.

  2010cited by this paper
• Evidence for Antibody-Mediated Injury as a Major Determinant of Late Kidney Allograft Failure

  2010cited by this paper
• Reducing De Novo Donor‐Specific Antibody Levels during Acute Rejection Diminishes Renal Allograft Loss

  2009cited by this paper
• HLA-Specific Antibodies Developed in the First Year Posttransplant are Predictive of Chronic Rejection and Renal Graft Loss

  2009cited by this paper
• Human Leukocyte Antigen Antibodies and Chronic Rejection: From Association to Causation

  2008cited by this paper
• Development of Posttransplant Antidonor HLA Antibodies Is Associated with Acute Humoral Rejection and Early Graft Dysfunction

  2005cited by this paper
• Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome1

  2003cited by this paper
• Protocol biopsies should be part of the routine management of kidney transplant recipients. Pro.

  2002cited by this paper
• Subclinical Rejection in Tacrolimus-Treated Renal Transplant Recipients

  2002cited by this paper
• IMPACT OF DONOR-SPECIFIC ANTIBODIES ON CHRONIC REJECTION OCCURRENCE AND GRAFT LOSS IN RENAL TRANSPLANTATION: POSTTRANSPLANT ANALYSIS USING FLOW CYTOMETRIC TECHNIQUES1

  2001cited by this paper
• Beneficial effects of treatment of early subclinical rejection: a randomized study.

  1998cited by this paper
• Histologic features of chronic allograft nephropathy revealed by protocol biopsies in kidney transplant recipients.

  1998cited by this paper
• Flow cytometry analysis: A high technology cross-match technique facilitating transplantation

  1983cited by this paper
• Significance of the positive crossmatch test in kidney transplantation.

  1969cited by this paper

• Cross-organ hierarchy of HLA molecular mismatches in donor-specific antibody development in solid organ transplantations

  2025cites this paper
• Role of human leucocyte antigen (DQ) in acute renal allograft rejection: A single center study.

  2025cites this paper
• Germinal Center B Cells are Uniquely Targeted by Antibody-Suppressor CXCR5+CD8+ T Cells

  2025cites this paper
• Antibody-Suppressor CXCR5+CD8+ T Cells Are More Potent Regulators of Humoral Alloimmunity after Kidney Transplant in Mice Compared to CD4+ Regulatory T Cells.

  2024cites this paper
• The Impact of HLA-DQαβ Heterodimer Mismatch on Living Donor Kidney Allograft Outcomes

  2024cites this paper
• The Clinical Utility of Post-Transplant Monitoring of Donor-Specific Antibodies in Stable Renal Transplant Recipients: A Consensus Report With Guideline Statements for Clinical Practice

  2023cites this paper
• Biomarkers for Kidney-Transplant Rejection: A Short Review Study

  2023cites this paper
• Extended genomic HLA typing identifies previously unrecognized mismatches in living kidney transplantation

  2023cites this paper
• Clinical characteristics of renal transplant recipients who developed de novo donor-specific antigen in Kyoto University Hospital: a case series

  2022cites this paper
• Antibody‐suppressor CXCR5+CD8+ T cellular therapy ameliorates antibody‐mediated rejection following kidney transplant in CCR5 KO mice

  2022cites this paper
• Rationale for the IMAGINE study for chronic active antibody‐mediated rejection (caAMR) in kidney transplantation

  2022cites this paper
• The Clinical Impact of Anti-HLA Donor Specific Antibody Detection Through First Year Screening on Stable Kidney Transplant Recipients

  2022cites this paper
• Donor HLA genotyping of ex vivo expanded urine cells from kidney transplant recipients

  2021cites this paper
• Impact of the immunotherapy induction on allograft outcome and survival in kidney transplant patients with donor-specific antibodies to HLA-DQB1.

  2021cites this paper
• Antibody-Mediated Rejection and Recurrent Primary Disease: Two Main Obstacles in Abdominal Kidney, Liver, and Pancreas Transplants

  2021cites this paper
• Immunologic Challenges Pre-transplant

  2021cites this paper
• Clinical Outcome of Kidney Transplant Patients on the Allograft Function, Loss, Effects of HLA-DQB1-DSA+, and Graft Survival.

  2021cites this paper
• Inverse Association Between the Quantity of Human Peripheral Blood CXCR5+IFN-γ+CD8+ T Cells With De Novo DSA Production in the First Year After Kidney Transplant

  2020cites this paper
• Analysis of Risk Factors and Long-Term Outcomes in Kidney Transplant Patients with Identified Lymphoceles

  2020cites this paper
• Eplet mismatches associated with de novo donor-specific HLA antibody in pediatric kidney transplant recipients

  2020cites this paper
• Aus der Klinik mit Schwerpunkt Nephrologie und Intensivmedizin der Medizinischen Fakultät Charité – Universitätsmedizin Berlin DISSERTATION Use of interferon-stimulated gene expression level in renal transplant patients’ blood as biomarkers for diagnosis of rejection zur Erlangung des akademische

  2020cites this paper
• Screening strategy for de novo donor‐specific HLA antibodies beyond the first year after kidney transplantation: Personalized or “one size fits all”?

  2020cites this paper
• C1q‐binding DSA and allograft outcomes in pediatric kidney transplant recipients

  2020cites this paper
• Modulating the wayward T cell: New horizons with immune checkpoint inhibitor treatments in autoimmunity, transplant, and cancer.

  2020cites this paper
• An optimised ensemble for antibody-mediated rejection status prediction in kidney transplant patients

  2020cites this paper
• Analysis of Risk Factors and Long-Term Outcomes in Kidney Transplant Patients with Identified Lymphoceles

  2020cites this paper
• Monitoring of Donor-specific Anti-HLA Antibodies and Management of Immunosuppression in Kidney Transplant Recipients: An Evidence-based Expert Paper.

  2020cites this paper
• What have we learned about how to prevent and treat antibody‐mediated rejection in kidney transplantation?

  2020cites this paper
• Mechanisms of organ transplant injury mediated by B cells and antibodies: Implications for antibody‐mediated rejection

  2020cites this paper
• The value of high-resolution HLA in the perioperative period of non-sensitized lung transplant recipients.

  2020cites this paper
• Post-transplant donor specific antibody is associated with poor kidney transplant outcomes only when combined with both T-cell-mediated rejection and non-adherence.

  2019cites this paper
• Tacrolimus Variability: A Cause of Donor-Specific Anti-HLA Antibody Formation in Children

  2019cites this paper
• Outstanding questions in transplantation: B cells, alloantibodies, and humoral rejection

  2019cites this paper
• Multicentre randomised controlled trial protocol of urine CXCL10 monitoring strategy in kidney transplant recipients

  2019cites this paper
• Biomarkers of Kidney Injury and Rejection

  2019cites this paper
• Characteristics and predictive value for graft fibrosis of the complement‐binding capacity of donor‐specific human leukocyte antigen antibodies after pediatric liver transplantation

  2019cites this paper
• Should We Revisit HLA Matching to Improve Long-Term Graft Outcomes?

  2018cites this paper
• Donor‐specific anti‐HLA antibodies are not associated with nonanastomotic biliary strictures but both are independent risk factors for graft loss after liver transplantation

  2018cites this paper
• Meeting report: FDA public meeting on patient‐focused drug development and medication adherence in solid organ transplant patients

  2018cites this paper
• Impact of persistent and cleared preformed HLA DSA on kidney transplant outcomes.

  2018cites this paper
• HLA-DQ Mismatching and Kidney Transplant Outcomes.

  2018cites this paper
• Impact of reduced exposure to calcineurin inhibitors on the development of de novo DSA: a cohort of non-immunized first kidney graft recipients between 2007 and 2014

  2018cites this paper
• Carpe diem—Time to transition from empiric to precision medicine in kidney transplantation

  2018cites this paper
• Early clearance vs persistence of de novo donor‐specific antibodies following lung transplantation

  2017cites this paper
• Intravenous immunoglobulin therapy in kidney transplant recipients with de novo DSA: Results of an observational study

  2017cites this paper
• The detrimental impact of persistent vs an isolated occurrence of de novo donor‐specific antibodies on intermediate‐term renal transplant outcomes

  2017cites this paper
• Racial differences in incident de novo donor‐specific anti‐HLA antibody among primary renal allograft recipients: results from a single center cohort study

  2017cites this paper
• De Novo Donor-Specific Antibody Formation in Tacrolimus-Based, Mycophenolate Versus Mammalian Target of Rapamycin Immunosuppressive Regimens.

  2017cites this paper
• C1q binding is not an independent risk factor for kidney allograft loss after an acute antibody‐mediated rejection episode: a retrospective cohort study

  2017cites this paper
• Acute antibody-mediated rejection in kidney transplant recipients.

  2017cites this paper
• Optimizing tacrolimus treatment in kidney transplant recipients

  2017cites this paper
• Pre‐existing donor‐specific antibodies are detrimental to kidney allograft only when persistent after transplantation

  2017cites this paper
• Impact of De Novo Donor-specific Alloantibody in Primary Renal Allografts

  2017cites this paper
• Disparate rates of acute rejection and donor‐specific antibodies among high‐immunologic risk renal transplant subgroups receiving antithymocyte globulin induction

  2016cites this paper
• Impact of de novo donor‐specific anti‐HLA antibodies on grafts outcomes in simultaneous pancreas–kidney transplantation

  2016cites this paper
• HLA-DQ Mismatching: Mounting Evidence for a Role in Kidney Transplant Rejection.

  2016cites this paper
• Propriétés des anticorps anti-HLA en transplantation d'organes

  2016cites this paper
• Minimum mycophenolic acid levels are associated with donor‐specific antibody formation

  2016cites this paper
• HLA-DQ Mismatches and Rejection in Kidney Transplant Recipients.

  2016cites this paper
• Clinically relevant interpretation of solid phase assays for HLA antibody

  2016cites this paper
• Low‐target tacrolimus in de novo standard risk renal transplant recipients: A single‐centre experience

  2016cites this paper
• The Humoral Theory of Transplantation: Epitope Analysis and the Pathogenicity of HLA Antibodies

  2016cites this paper
• Immunobiology of Allograft Human Leukocyte Antigens in the New Microenvironment

  2015cites this paper
• Non-invasive diagnosis of acute rejection in renal transplant patients using mass spectrometry of urine samples - a multicentre phase 3 diagnostic accuracy study

  2015cites this paper
• Impact of de novo donor-specific anti-HLA antibodies on grafts outcomes in simultaneous pancreas-kidney

  2015cites this paper
• Humoral Immune Response and Allograft Function in Kidney Transplantation.

  2015cites this paper
• Characteristics of Circulating Donor Human Leukocyte Antigen-specific Immunoglobulin G Antibodies Predictive of Acute Antibody-mediated Rejection and Kidney Allograft Failure

  2015cites this paper
• One-year protocol biopsies from ABO-incompatible renal allografts compared with a matched cohort of ABO-compatible allografts

  2015cites this paper
• Onset and progression of de novo donor‐specific anti‐human leukocyte antigen antibodies after BK polyomavirus and preemptive immunosuppression reduction

  2015cites this paper
• Model of Chronic Allograft Injury in Alloantibody Positive Renal Transplant Patients

  2015cites this paper
• Recent advances in renal interstitial fibrosis and tubular atrophy after kidney transplantation

  2014cites this paper
• Performance of the ImmuKnow assay in differentiating infection and acute rejection after kidney transplantation: a meta-analysis.

  2014cites this paper
• Analysis of predictive and preventive factors for de novo donor-specific antibodies in kidney transplant recipientsy--is nonadherence of importance?

  2014cites this paper
• International Journal of Organ Transplantation Medicine Acute Rejection in Renal Transplant Patients of a Hospital in Bogota, Colombia

  year unknowncites this paper